Cardiac Resynchronization Therapy News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.EBR Systems raises $20m for wireless pacer
EBR Systems raises $20 million to propel development and regulatory approval of its wireless cardiac resynchronization therapy device.
EBR Systems Inc.News Well, Cardiac Rhythm Management, Funding Roundupread more (Source: Mass Device)
Source: Mass Device - April 10, 2015 Category: Medical Equipment Authors: Mark Hollmer Source Type: news
Some With CRT Might Have Ablation-Amenable PVC CardiomyopathySome With CRT Might Have Ablation-Amenable PVC Cardiomyopathy
Could ablation have helped? Frequent ectopic beats arising from the RV outflow tract were a suspected source of non-CAD cardiomyopathy leading to cardiac resynchronization therapy in a major trial. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news
St. Jude Medical Announces CE Mark Approval Of The World's Only MultiPoint Pacing Pacemaker
St. Jude Medical, Inc., a global medical device company, recently announced CE Mark approval of the Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P). (Source: Medical Design Online News)
Source: Medical Design Online News - December 15, 2014 Category: Medical Equipment Source Type: news
Medtronic Receives FDA Approval And Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads
Medtronic, Inc. recently announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat patients with heart failure. (Source: Medical Design Online News)
Source: Medical Design Online News - December 12, 2014 Category: Medical Equipment Source Type: news
Medtronic wins FDA approval for more Attain Performa quad defib leads
Medtronic says it won pre-market approval from the FDA for another pair of Attain Performa quadripolar cardiac resynchronization therapy defibrillator leads.
Food & Drug Administration (FDA), MedtronicNews Well, Cardiac Rhythm Management, Pre-Market Approval (PMA), Regulatory/Complianceread more (Source: Mass Device)
Source: Mass Device - December 11, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news
St. Jude Medical wins CE Mark for Quadra Allure MP pacemaker
St. Jude Medical says it won CE Mark approval in the European Union for its Quadra Allure MP pacemaker, claiming it as the sole cardiac resynchronization therapy pacemaker to offer multi-point pacing.
St. Jude MedicalNews Well, Cardiac Rhythm Management, CE Markread more (Source: Mass Device)
Source: Mass Device - December 11, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news
Medtronic touts CRT data
Meta-analyses of Medtronic-sponsored studies show the clinical and economic benefits of its cardiac resynchronization therapy devices.
Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio.
MedtronicNews Well, Cardiac Rhythm Managementread more (Source: Mass Device)
Source: Mass Device - November 17, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news
ESC: Quadripolar Tops Bipolar in Cardiac Pacing (CME/CE)
BARCELONA (MedPage Today) -- Quadripolar left ventricle lead technology dramatically reduced perioperative complications in implanting cardiac pacemakers for cardiac resynchronization therapy, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 31, 2014 Category: Cardiology Source Type: news
Medtronic launches personalized heart rhythm therapy trial
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.
Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.
MedtronicNews Well, Clinical Trials, Cardiac Implants, Cardiac Rhythm Management, Implants, Minnesotaread more (Source: Mass Device)
Source: Mass Device - August 27, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news
Medtronic's personalized pacemaker wins FDA approval
FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block.
Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute.
MedtronicNews Well, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 25, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news
Press Release: Medtronic Viva cardiac resynchronization therapy-pacemaker now available in U.S.
AdaptivCRT algorithm customizes therapy for heart failure patients and improves their response rates.
MINNEAPOLIS - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.
MedtronicNews Well, Press Release, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 25, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news
Implantable heart devices result in similar survival benefits among ethnic, racial groups
Racial and ethnic minorities who receive implantable devices to treat heart failure derive the same substantial survival benefit from these therapies as white patients, new UCLA-led research shows.
While the American College of Cardiology and American Heart Association jointly recommend the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices for all eligible patients, minorities have not been well represented in clinical trials of the devices, and previous studies had shown that African American and Hispanic patients are less likely to receive these recommended therapie...
Source: UCLA Newsroom: Health Sciences - August 18, 2014 Category: Universities & Medical Training Source Type: news
Medtronic Receives FDA Approval For Attain Performa Quadripolar Lead And Viva Quad CRT-Ds In United States
Medtronic, Inc. recently announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D). (Source: Medical Design Online News)
Source: Medical Design Online News - August 11, 2014 Category: Medical Equipment Source Type: news
Medtronic brings new smart pacemaker to India | MassDevice.com On Call
Medtech titan Medtronic launched a new cardiac resynchronization therapy-pacemaker for the Indian market after landing CE Mark approval in the European Union earlier this year.
MASSDEVICE ON CALL — Medtronic (NYSE:MDT) this week announced that it's bringing its Viva cardiac resynchronization therapy-pacemaker to the market in India, a country where Medtronic is banking on significant growth.
MedtronicNews Well, Emerging Markets, On Call, Cardiac Rhythm Management, Minnesotaread more (Source: Mass Device)
Source: Mass Device - August 8, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news
